VISTAGEN THERAPEUTICS, INC. Deferred Costs, Current
VISTAGEN THERAPEUTICS, INC. (VTGN) had Deferred Costs, Current of $74.00 thousand as of 2024-03-31, per its 10-K filed 2024-06-11.
Discontinued › Balance Sheet › Assets › Assets, Current › Deferred Costs, Current
us-gaap:DeferredCostsCurrent · last filed 2024-06-11
- 2024-03-31: Deferred Costs, Current $74.00K.
- 2023-12-31: Deferred Costs, Current $74.50K.
- 2023-09-30: Deferred Costs, Current $74.50K.
- 2023-06-30: Deferred Costs, Current $67.10K.
| Period end | Deferred Costs, Current | Deferred Costs, Current as first filed |
|---|---|---|
| 2024-03-31 | $74.00K 10-K · filed 2024-06-11 | |
| 2023-12-31 | $74.50K 10-Q · filed 2024-02-13 | |
| 2023-09-30 | $74.50K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $67.10K 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $67.00K 10-K · filed 2024-06-11 | $67.10K 10-K · filed 2023-06-28 |
| 2022-12-31 | $67.00K 10-Q · filed 2023-02-07 | |
| 2022-09-30 | $67.00K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $116.90K 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $116.90K 10-K · filed 2023-06-28 | |
| 2021-12-31 | $133.50K 10-Q · filed 2022-02-10 | |
| 2021-09-30 | $133.50K 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $133.50K 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $133.50K 10-K · filed 2022-06-23 | |
| 2020-12-31 | $116.90K 10-Q · filed 2021-02-11 | |
| 2020-09-30 | $116.90K 10-Q · filed 2020-11-12 | |
| 2020-03-31 | $0.00 10-K · filed 2021-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |